The iron deficiency injectable market is expected to reach approximately USD 23,874.19 million by 2032. This represents a significant increase from its 2024 projection of USD 12,045.95 million, highlighting the market’s strong growth.
The market is experiencing a compound annual growth rate (CAGR) of 8.93%. This rapid growth rate is primarily driven by the increasing global prevalence of iron deficiency and related disorders.
Injectable iron supplements are often prescribed when oral treatments are ineffective or inappropriate. They offer a faster and more efficient way to increase hemoglobin levels in patients with iron deficiency, particularly benefiting those who cannot tolerate oral iron supplements.
Key factors include rising awareness of iron deficiency anemia, advancements in injectable iron formulations, and a growing focus on parenteral iron therapy. Additionally, the increasing number of patients undergoing dialysis, who often require parenteral iron, and the rising number of pregnancies globally, also contribute to this market growth.